Cellbox Solutions, a Germany-based developer of portable CO2 incubators, has raised €3.5M ($4M) in the first tranche of a Series A round led by Companisto and NRW.BANK. The devices maintain 37°C and 5% CO2 for live cell and tissue transport during shipping. The capital will fund international production and sales expansion plus applications in cell/gene therapy and IVF.
CGT Logistics Market Heats Up
The raise aligns with surging demand in cell and gene therapy logistics: Cryoport launched Elite Ultra Cold for gene therapy in December 2024, while the sector sees renewed investment per BioSpace's October 2024 report. Cellbox's active control differentiates from Cryoport's cold chain focus. Over 150 customers already use its devices worldwide.
Cryopreservation Limits Cell Viability
Cell and gene therapies face transport challenges, with cryopreservation causing up to 60% cell loss and recovery delays. Traditional dry ice shipping fails for sensitive cells like NK cells and organoids. Live shipment preserves 2.5x more functionality versus cryo, per Fraunhofer studies.
Active Incubators Enable Warm Shipping
Cellbox offers battery-powered units like Cellbox Go for short flights and Cellbox Shipper for 48-hour hauls, both IATA-certified with app monitoring. Unlike Hemanext's ($128M raised) hypoxic blood storage or Atelerix's ($2.4M) microfluidics, Cellbox provides broad active CO2/temp control for diverse biologics. Partnerships with BioSpherix and World Courier validate its workflow integration.
As Prof. Dr. Kathrin Adlkofer, CEO, noted:
"Our vision is to redefine how living cells are transported globally."
Investor Backing Signals Scale Potential
Companisto's lead investment reflects conviction in Cellbox's platform amid €33M+ in recent European life sciences funding. NRW.BANK's participation adds regional growth support. This follows pre-Series A and EIC grants, bringing total funding near $11M.
Logistics Market Doubles by 2030
Cell/gene therapy third-party logistics stands at $10.71B in 2024, projected to reach $20.04B by 2030 at 11.05% CAGR. Drivers include 1000+ CGT candidates and global trials. Competitors like PHCbi focus on stationary incubators, leaving gaps in portable live transport that Cellbox fills.
Serial Founder Boosts Credibility
CEO Kathrin Adlkofer brings 20+ years, including Evotec business development and leading life sciences clusters. Chairman Timm-H Jessen, a serial founder, saw Bionamics acquired by Evotec, 2cureX IPO in 2017, and Topas Therapeutics raise $48M+ Series B. Their exits provide fundraising and partnership expertise for Cellbox's global push.
Expansion Targets US and IVF
Funds enable US subsidiary growth via recent Cellbox Solutions Inc. setup, plus hires in R&D, sales, and finance. New distributor in Austria and Ireland signal EMEA traction. Peer-reviewed NK cell transport success paves for IVF and organoid apps.